Aegis Reaffirms Buy Rating for Yield10 Bioscience (NASDAQ:YTEN)

Share on StockTwits

Aegis reissued their buy rating on shares of Yield10 Bioscience (NASDAQ:YTEN) in a report released on Tuesday morning, AnalystRatings.com reports. They currently have a $2.00 price objective on the specialty chemicals company’s stock.

“We expect a repeat on 2018 field trials with positive results, especially within C3003 in canola and camelina which should help YTEN pull forward collaboration with the company’s large AG major partners. In addition to canola and camelina, YTEN is also engaged with third parties interested in corn, soybean, wheat, and rice. The Trait Factory” is helping to broaden YTEN’s product portfolio. The company has identified three new sectors which could present additional opportunities for for long-term growth; PHA Pharmaceuticals (CBD). We believe the company’s broadening of its core assets as a positive. YTEN expects commercialization could occur within six years, as discussions are ongoing with possible partners.”,” the firm’s analyst commented.

Other research analysts have also recently issued research reports about the company. Maxim Group reiterated a buy rating and issued a $3.00 target price on shares of Yield10 Bioscience in a report on Friday, May 31st. Zacks Investment Research upgraded Yield10 Bioscience from a sell rating to a hold rating in a report on Sunday, July 14th. Finally, National Securities reiterated a buy rating and issued a $5.00 target price on shares of Yield10 Bioscience in a report on Tuesday.

Shares of NASDAQ:YTEN opened at $0.95 on Tuesday. The company has a market cap of $12.87 million, a P/E ratio of -1.03 and a beta of 3.21. The company has a quick ratio of 4.49, a current ratio of 4.49 and a debt-to-equity ratio of 0.87. Yield10 Bioscience has a 52 week low of $0.68 and a 52 week high of $1.77. The business has a fifty day simple moving average of $0.92 and a 200-day simple moving average of $1.03.

Yield10 Bioscience (NASDAQ:YTEN) last issued its earnings results on Monday, August 12th. The specialty chemicals company reported ($0.15) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.21) by $0.06. Yield10 Bioscience had a negative return on equity of 134.51% and a negative net margin of 1,320.21%. The firm had revenue of $0.32 million for the quarter. Sell-side analysts expect that Yield10 Bioscience will post -0.58 earnings per share for the current fiscal year.

An institutional investor recently raised its position in Yield10 Bioscience stock. Renaissance Technologies LLC boosted its position in Yield10 Bioscience Inc (NASDAQ:YTEN) by 9.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 478,176 shares of the specialty chemicals company’s stock after acquiring an additional 41,500 shares during the quarter. Renaissance Technologies LLC owned 3.83% of Yield10 Bioscience worth $463,000 as of its most recent filing with the Securities and Exchange Commission. 7.43% of the stock is currently owned by institutional investors.

Yield10 Bioscience Company Profile

Yield10 Bioscience, Inc, an agricultural bioscience company, engages in developing disruptive technologies for enhancing crop yield in the United States and Canada. The company, through its Smart Carbon Grid for Crops and T3 platforms, is involved in improving fundamental crop yield through enhanced photosynthetic carbon capture, as well as increased carbon utilization efficiency to increase seed yield.

Recommended Story: Why are percentage decliners important?

Receive News & Ratings for Yield10 Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Yield10 Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Meridian Bioscience  Cut to Sell at ValuEngine
Meridian Bioscience Cut to Sell at ValuEngine
Trevena  Raised to “Buy” at Zacks Investment Research
Trevena Raised to “Buy” at Zacks Investment Research
2U  Now Covered by Analysts at William Blair
2U Now Covered by Analysts at William Blair
Aegis Reaffirms Buy Rating for Yield10 Bioscience
Aegis Reaffirms Buy Rating for Yield10 Bioscience
SunOpta, Inc.  Director Acquires $156,748.80 in Stock
SunOpta, Inc. Director Acquires $156,748.80 in Stock
First Majestic Silver Corp.  Senior Officer Sells C$179,375.00 in Stock
First Majestic Silver Corp. Senior Officer Sells C$179,375.00 in Stock


© 2006-2019 Ticker Report